Inside informationEnglish
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- DBV Technologies
- Filed
- 16/12/2025, 22:05
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 115291_20251216